Latest Breaking News On - Ulka nitin vaishampayan - Page 1 : comparemela.com

Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

United statesUlka nitin vaishampayanUniversity of michiganPhasei program at rogel cancer centerInternational kidney cancer symposiumPhasei programRogel cancer centerKidney cancer symposiumOnclive tvGenitourinary cancerRenal cell carcinoma

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

United statesUlka nitin vaishampayanUniversity of michiganRogel cancer centerPhasei programTalazoparib and enzalutamideHrr gene mutated

Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC

Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.

Ann arborUnited statesClara hwangUlka nitin vaishampayanShawna kraftSarah yentzPhasei programUniversity of michigan rogel cancer centerRogel cancer centerUniversity of michiganHenry ford healthScience summitMichigan rogel cancer centerPatients with metastatic renal cell carcinomaThe university of michiganTreatment updates across prostate cancer

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

United statesUlka nitin vaishampayanPhasei programRogel cancer centerUniversity of michiganOnclive tvNon metastatic castration resistant prostate cancer

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesUlka nitin vaishampayanPhasei program at rogel cancer centerUniversity of michiganPhasei programRogel cancer center